Evusheld significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations
- Details
- Category: AstraZeneca

GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9bn
- Details
- Category: GlaxoSmithKline

Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board
- Details
- Category: Sanofi

Pfizer to acquire ReViral and its respiratory syncytial virus therapeutic candidates
- Details
- Category: Pfizer

Novartis announces new organizational structure
- Details
- Category: Novartis

U.S. FDA grants priority review to Roche's Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults
- Details
- Category: Roche

Roche donates additional medicines and diagnostics for Ukraine
- Details
- Category: Roche

Beyond the already communicated 150,000 packs of an antibiotic medicine the new donation includes another 4,600 packs of specialized medicines for the treatment of influenza, rheumatoid arthritis, SMA and various cancers.
More Pharma News ...
- Pfizer and BioNTech receive expanded U.S. emergency use authorization for an additional COVID-19 vaccine booster in individuals aged 50 years and older
- Evusheld long-acting antibody combination recommended for approval in the EU for the pre-exposure prophylaxis (prevention) of COVID-19
- Pfizer to supply UNICEF up to 4 million treatment courses of novel COVID-19 oral treatment for low- and middle-income countries
- Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates
- Pfizer and BioNTech aubmit for U.S. Emergency Use Authorization of an additional booster dose of their COVID-19 vaccine for older adults
- Pfizer updates company position in Russia
- Novartis signs initial agreement with Carisma Therapeutics for the manufacturing of HER 2 targeted CAR-M cell therapy